Sold as Terramycin. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Oxytetracycline (sold as Terramycin), with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Combination Therapy of Anthracyclines for Children With Nephroblastoma0.5-14 Year Old Children With Nephroblastoma · Shengjing Hospital | Phase 4 | Not yet recruiting | Mar 27, 2019 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| — | TerramycinNDA 50287 | Pfizer | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer